Pyrrole-protein adducts – A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity

Roeder, 1995, Medicinal-plants in Europe containing pyrrolizidine alkaloids, Pharmazie, 50, 83 Roeder, 2000, Medicinal plants in China containing pyrrolizidine alkaloids, Pharmazie, 55, 711 Wiedenfeld, 2011, Toxicity of pyrrolizidine alkaloids to humans and ruminants, Phytochem Rev, 10, 137, 10.1007/s11101-010-9174-0 Roulet, 1988, Hepatic veno-occlusive disease in newborn-infant of a woman drinking herbal tea, J Pediatr, 112, 433, 10.1016/S0022-3476(88)80330-5 Ruan, 2015, Blood pyrrole-protein adducts-A biomarker of pyrrolizidine alkaloid-induced liver injury in humans, J Environ Sci Health Part C – Environ Carcinog Ecotoxicol, 33, 404, 10.1080/10590501.2015.1096882 Lin, 2011, Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum, J Hepatol, 54, 666, 10.1016/j.jhep.2010.07.031 Martinello, 2014, Easy and rapid method for the quantitative determination of pyrrolizidine alkaloids in honey by ultra performance liquid chromatography-mass spectrometry: an evaluation in commercial honey, Food Contr, 37, 146, 10.1016/j.foodcont.2013.09.037 Prakash, 1999, Pyrrolizidine alkaloids in human diet, Mutat Res Genet Toxicol Environ Mutag, 443, 53, 10.1016/S1383-5742(99)00010-1 Rasenack, 2003, Veno-occlusive disease in a fetus caused by pyrrolizidine alkaloids of food origin, Fetal Diagn Ther, 18, 223, 10.1159/000070799 Panter, 1990, Natural plant toxicants in milk - a review, J Anim Sci, 68, 892, 10.2527/1990.683892x Edgar, 2011, Pyrrolizidine alkaloids in food: a spectrum of potential health consequences, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 28, 308, 10.1080/19440049.2010.547520 Chojkier, 2003, Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids, J Hepatol, 39, 437, 10.1016/S0168-8278(03)00231-9 DeLeve, 1999, Characterization of a reproducible rat model of hepatic veno-occlusive disease, Hepatology, 29, 1779, 10.1002/hep.510290615 Gomez-Arroyo, 2012, The monocrotaline model of pulmonary hypertension in perspective, Am J Physiol Lung Cell Mol Physiol, 302, L363, 10.1152/ajplung.00212.2011 Stenmark, 2009, Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure, Am J Physiol Lung Cell Mol Physiol, 297, L1013, 10.1152/ajplung.00217.2009 Willmot, 1920, Senecio disease, or cirrhosis of the liver due to senecio poisoning, Lancet, 2, 848, 10.1016/S0140-6736(01)00020-4 Dai, 2007, Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature, World J Gastroenterol, 13, 1628, 10.3748/wjg.v13.i10.1628 Mohabbat, 1976, Outbreak of hepatic veno-occlusive disease in northwestern Afghanistan, Lancet, 2, 269, 10.1016/S0140-6736(76)90726-1 Robinson, 2014, Hirmi Valley liver disease: a disease associated with exposure to pyrrolizidine alkaloids and DDT, J Hepatol, 60, 96, 10.1016/j.jhep.2013.07.039 Gao, 2015, Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome, Drug Des Dev Ther, 9, 4861, 10.2147/DDDT.S87858 Zhuge, 2018, Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease, Liver Int, 10.1111/liv.13684 Edgar, 2014, Food contaminants capable of causing cancer, pulmonary hypertension and cirrhosis, Med J Aust, 200, 73, 10.5694/mja13.10227 Edgar, 2015, Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease, Chem Res Toxicol, 28, 4, 10.1021/tx500403t Fu, 2004, Pyrrolizidine alkaloids–genotoxicity, metabolism enzymes, metabolic activation, and mechanisms, Drug Metab Rev, 36, 1, 10.1081/DMR-120028426 Li, 2011, Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs, Curr Drug Metab, 12, 823, 10.2174/138920011797470119 Fu, 2017, Pyrrolizidine alkaloids: metabolic activation pathways leading to liver tumor initiation, Chem Res Toxicol, 30, 81, 10.1021/acs.chemrestox.6b00297 Ruan, 2014, Lack of metabolic activation and predominant formation of an excreted metabolite of nontoxic platynecine-type pyrrolizidine alkaloids, Chem Res Toxicol, 27, 7, 10.1021/tx4004159 Lin, 2000, Characterization of rat liver microsomal metabolites of clivorine, an hepatotoxic otonecine-type pyrrolizidine alkaloid, Drug Metab Dispos, 28, 1475 Kim, 1995, Pyrrolizidine alkaloid-induced DNA-protein cross-links, Carcinogenesis, 16, 2691, 10.1093/carcin/16.11.2691 Fu, 2001, Genotoxic pyrrolizidine alkaloids and pyrrolizidine alkaloid N-oxides – mechanisms leading to DNA adduct formation and tumorigenicity, J Environ Sci Health Part C – Environ Carcinog Ecotoxicol, 19, 353, 10.1081/GNC-100107580 Zhao, 2012, Full structure assignments of pyrrolizidine alkaloid DNA adducts and mechanism of tumor initiation, Chem Res Toxicol, 25, 1985, 10.1021/tx300292h Xia, 2013, Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity, Chem Res Toxicol, 26, 1384, 10.1021/tx400241c Yang, 2016, Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity, Chem Biol Interact, 243, 119, 10.1016/j.cbi.2015.09.011 Zhu, 2017, The long persistence of pyrrolizidine alkaloid-derived DNA adducts in vivo: kinetic study following single and multiple exposures in male ICR mice, Arch Toxicol, 91, 949, 10.1007/s00204-016-1713-z Mattocks, 1986 Ruan, 2014, Metabolic activation of pyrrolizidine alkaloids: insights into the structural and enzymatic basis, Chem Res Toxicol, 27, 1030, 10.1021/tx500071q Xia, 2016, Pyrrolizidine alkaloid-protein adducts: potential non-invasive biomarkers of pyrrolizidine alkaloid-induced liver toxicity and exposure, Chem Res Toxicol, 29, 1282, 10.1021/acs.chemrestox.6b00120 Estep, 1990, N-acetylcysteine-conjugated pyrrole identified in rat urine following administration of two pyrrolizidine alkaloids, monocrotaline and senecionine, Toxicol Lett, 54, 61, 10.1016/0378-4274(90)90056-R He, 2016, 7-N-Acetylcysteine-pyrrole conjugate-A potent DNA reactive metabolite of pyrrolizidine alkaloids, J Food Drug Anal, 24, 682, 10.1016/j.jfda.2016.08.001 He, 2017, 7-Glutathione-pyrrole and 7-cysteine-pyrrole are potential carcinogenic metabolites of pyrrolizidine alkaloids, J Environ Sci Health Part C – Environ Carcinog Ecotoxicol, 35, 69, 10.1080/10590501.2017.1298358 He, 2016, 7-cysteine-pyrrole conjugate: a new potential DNA reactive metabolite of pyrrolizidine alkaloids, J Environ Sci Health Part C – Environ Carcinog Ecotoxicol, 34, 57, 10.1080/10590501.2015.1135593 Xia, 2015, 7-Glutathione pyrrole adduct: a potential DNA reactive metabolite of pyrrolizidine alkaloids, Chem Res Toxicol, 28, 615, 10.1021/tx500417q Li, 2016, Lysine adduction by reactive metabolite(s) of monocrotaline, Chem Res Toxicol, 29, 333, 10.1021/acs.chemrestox.5b00488 Zhao, 2014, Reaction of dehydropyrrolizidine alkaloids with valine and hemoglobin, Chem Res Toxicol, 27, 1720, 10.1021/tx5002139 Mattocks, 1990, Recovery of the pyrrolic nucleus of pyrrolizidine alkaloid metabolites from sulfur conjugates in tissues and body-fluids, Chem Biol Interact, 75, 225, 10.1016/0009-2797(90)90120-C Mattocks, 1992, Chemistry of sulphur-bound pyrrolic metabolites in the blood of rats given different types of pyrrolizidine alkaloid, Nat Toxins, 1, 89, 10.1002/nt.2620010206 Pumford, 1997, Protein targets of xenobiotic reactive intermediates, Annu Rev Pharmacol Toxicol, 37, 91, 10.1146/annurev.pharmtox.37.1.91 Zhou, 2005, Drug bioactivation, covalent binding to target proteins and toxicity relevance, Drug Metab Rev, 37, 41, 10.1081/DMR-200028812 Deleve, 1991, Glutathione metabolism and its role in hepatotoxicity, Pharmacol Ther, 52, 287, 10.1016/0163-7258(91)90029-L Yan, 1995, Relationship between glutathione concentration and metabolism of the pyrrolizidine alkaloid, monocrotaline, in the isolated, perfused liver, Toxicol Appl Pharmacol, 130, 132, 10.1006/taap.1995.1017 DeLeve, 1996, Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease, Hepatology, 23, 589, 10.1002/hep.510230326 DeLeve, 2003, Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome, Am J Physiol Gastr L, 284, G1045, 10.1152/ajpgi.00526.2002 Lame, 2000, Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells, J Biol Chem, 275, 29091, 10.1074/jbc.M001372200 Lame, 2005, Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membranes of human pulmonary artery endothelial cells, Proteomics, 5, 4398, 10.1002/pmic.200402022 Wilson, 1998, Monocrotaline pyrrole interacts with actin and increases thrombin-mediated permeability in pulmonary artery endothelial cells, Toxicol Appl Pharmacol, 152, 138, 10.1006/taap.1998.8488 DeLeve, 2002, Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease), Semin Liver Dis, 22, 27, 10.1055/s-2002-23204 DeLeve, 2003, Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition, Gastroenterology, 125, 882, 10.1016/S0016-5085(03)01056-4 Mingatto, 2007, Dehydromonocrotaline inhibits mitochondrial complex I. A potential mechanism accounting for hepatotoxicity of monocrotaline, Toxicon, 50, 724, 10.1016/j.toxicon.2007.06.006 Reid, 1998, Involvement of cytochrome P450 3A in the metabolism and covalent binding of C-14-monocrotaline in rat liver microsomes, J Biochem Mol Toxicol, 12, 157, 10.1002/(SICI)1099-0461(1998)12:3<157::AID-JBT4>3.0.CO;2-K Nakayama Wong, 2010, Differential cellular responses to protein adducts of naphthoquinone and monocrotaline pyrrole, Chem Res Toxicol, 23, 1504, 10.1021/tx1002436 Thomas, 1998, Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells, Toxicol Appl Pharmacol, 151, 236, 10.1006/taap.1998.8458 Thomas, 1998, Prolonged cell-cycle arrest associated with altered cdc2 kinase in monocrotaline pyrrole-treated pulmonary artery endothelial cells, Am J Respir Cell Mol Biol, 19, 129, 10.1165/ajrcmb.19.1.2895 Coulombe, 1999, Pyrrolizidine alkaloids crosslink DNA with actin, Toxicol Appl Pharmacol, 154, 198, 10.1006/taap.1998.8552 Hincks, 1991, DNA cross-linking in mammalian-cells by pyrrolizidine alkaloids - structure-activity-relationships, Toxicol Appl Pharmacol, 111, 90, 10.1016/0041-008X(91)90137-4 Mattocks, 1967, Spectrophotometric determination of unsaturated pyrrolizidine alkaloids, Anal Chem, 39, 443, 10.1021/ac60248a006 Mattocks, 1968, Toxicity of pyrrolizidine alkaloids, Nature, 217, 723, 10.1038/217723a0 Mattocks, 1970, Estimation of metabolites of pyrrolizidine alkaloids in animal tissues, Anal Biochem, 38, 529, 10.1016/0003-2697(70)90478-1 Mattocks, 1992, Detection of sulfur-conjugated pyrrolic metabolites in blood and fresh or fixed liver-tissue from rats given a variety of toxic pyrrolizidine alkaloids, Toxicol Lett, 63, 47, 10.1016/0378-4274(92)90106-T Schoch, 2000, GC/MS/MS detection of pyrrolic metabolites in animals poisoned with the pyrrolizidine alkaloid riddelliine, J Nat Toxins, 9, 197 Li, 2017, Immunoassay approach for diagnosis of exposure to pyrrolizidine alkaloids, J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 35, 127, 10.1080/10590501.2017.1328828 Church, 2018, Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort, Hepatology, 10.1002/hep.29802 Teschke, 2017, Drug induced liver injury: can biomarkers assist RUCAM in causality assessment?, Int J Mol Sci, 18, E803, 10.3390/ijms18040803 Weiler, 2015, Drug-induced liver injury: the dawn of biomarkers?, F1000Prime Rep, 7, 34, 10.12703/P7-34 Gao, 2012, Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids, J Dig Dis, 13, 33, 10.1111/j.1751-2980.2011.00552.x Yang, 2017, First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans, Arch Toxicol, 91, 3913, 10.1007/s00204-017-2013-y